The ability to differentiate stem cells (human or pluripotent (iPS)) into cardiomyocytes offers not only valuable tools for research in cardiovascular development but potentially a path to cell therapy. Current methods of differentiation into cardiomyocytes suffer from low yield and the hetergoneity in the derived cardiomyocytes. In addition, inconsistencies in serum and other biomolecules and the high costs of growth factors prevent the current protocols from being scalable.
The research team at the Icahn School of Medicine at Mount Sinai led by Dr Roger Hajjar has devised a novel method of producing cardiomyocytes from human stem cells in exceptionally high yields (>90%). Unlike current methods, this approach uses small molecules that are low cost which makes this protocol scalable and reproducible. The cardiomyocytes produced by this protocol exhibit physiological and molecular characteristic expected of human ventricular cardiomyocytes. Of particular significance, the resulting cell population is highly homogenous and does not require any genetic manipulation or cell sorting to give clinical- grade quality. Most importantly, these ventricular cardiomyocytes can be used in a variety of situations including cardiovascular regeneration, testing of cardioactive drugs and evaluation of cardiovascular toxicity of non-cardioactive drugs.
Patent Status : Patent Pending